Erratum
for
Sargent et al., J Clin Oncol 27 (12) 1948-1955.
Journal of Clinical Oncology, Vol 27, No 20 (July 10), 2009: pp. 3410-3411
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2009.24.4566
ERRATA
The April 20, 2009, article by Sargent et al, entitled, "Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer" (J Clin Oncol 27:1948–1955, 2009), contained errors in some of the data given for PFS and OS.
In the Results section, under Experimental Versus Control Arms, the third and fifth sentences were given as:
"For PFS, the experimental treatment provided a benefit in both PS 0 to 1 patients (HR = 0.81 for experimental v control treatment; 95% CI, 0.77 to 0.86; P < .00001; median PFS, 17.9 months for experimental treatment v 16.4 months for control) and PS2 patients (HR = 0.79 for experimental v control treatment; 95% CI, 0.66 to 0.96; P = .02; median PFS, 8.8 months for experimental treatment v 8.2 months for control)."
"Similarly, for the OS end point, the experimental treatment provided similar benefit in both PS 0 to 1 patients (HR = 0.87; 95% CI, 0.82 to 0.93; P < .00001; median OS, 8.4 months for experimental treatment v 6.7 months for control) and PS2 patients (HR = 0.88; 95% CI, 0.73 to 1.07; P = .21; median OS, 6.0 months for experimental treatment v 4.0 months for control)."
While they should have been:
"For PFS, the experimental treatment provided a benefit in both PS 0 to 1 patients (HR = 0.81 for experimental v control treatment; 95% CI, 0.77 to 0.86; P < .00001; median PFS, 8.4 months for experimental treatment v 6.7 months for control) and PS2 patients (HR = 0.79 for experimental v control treatment; 95% CI, 0.66 to 0.96; P = .02; median PFS, 6.0 months for experimental treatment v 4.0 months for control)."
"Similarly, for the OS end point, the experimental treatment provided similar benefit in both PS 0 to 1 patients (HR = 0.87; 95% CI, 0.82 to 0.93; P < .00001; median OS, 17.9 months for experimental treatment v 16.4 months for control) and PS2 patients (HR = 0.88; 95% CI, 0.73 to 1.07; P = .21; median OS, 8.8 months for experimental treatment v 8.2 months for control)."
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
